Results 141 to 150 of about 27,891 (313)

Semaglutide improves metabolic dysfunction‐associated steatohepatitis: A 10‐year retrospective study

JGH Open
Background and Aims Semaglutide has been studied in patients with metabolic dysfunction‐associated steatohepatitis (MASH) due to potential benefit from weight loss on liver inflammation.
Parth Shah, Megan White, Alex Sievert, Alexander Conway, Adam Kneepkens, Gregory Sayuk, Mauricio Lisker‐Melman, Jill Elwing   +7 more
doaj   +1 more source

Fast Quantitative Evaluation of the Amelioration Effect in MASLD During Semaglutide Treatment Using Ultrasound‐Derived Fat Fraction and Fat‐to‐Muscle Ratio

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a chronic liver disease. Research into a feasible, rapid, and effective assessment method is crucial for evaluating the therapeutic effects of semaglutide in MASLD. This prospective study utilized ultrasound‐derived fat fraction measurement and fat‐to‐muscle ratio to evaluate hepatic ...
Yunlin Huang, Ruping Yang, Ying Wang, Xiu‐Yun Lu, Li Wei, Rui Cheng, Juan Cheng, Yijie Qiu, Shiwen Wang, Bo Li, Yi Dong   +10 more
wiley   +1 more source

The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy

American journal of ophthalmology-glaucoma
PURPOSE: The association between GLP-1 receptor agonists (GLP-1RA) and nonarteritic anterior ischemic optic neuropathy (NAION) remains unclear. Given the de-bilitating sequelae of NAION and rapid increase of GLP-1RA use, further research is essential to ...
Nadia J. Abbass, Raya Nahlawi, Jacqueline K. Shaia, Kevin C. Allan, D. Kaelber, Katherine E. Talcott, Rishi P. Singh   +6 more
semanticscholar   +1 more source

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

Association of semaglutide treatment with coronary artery inflammation in type 2 diabetes mellitus patients: a retrospective study based on pericoronary adipose tissue attenuation

Cardiovascular Diabetology
Background The pericoronary fat attenuation index (FAI) has emerged as a novel and sensitive biomarker reflecting the degree of coronary artery inflammation.
Yanhong Li, Wenjing Yao, Tianxing Wang, Qian Yang, Kexin Song, Feifei Zhang, Fan Wang, Yi Dang   +7 more
doaj   +1 more source

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen, Li Ding, Shan Zhao, Weihong Wang, Jing Zhong, Qiang Yan   +5 more
wiley   +1 more source

Phytochemicals in MASLD: A Focused Review of Gut Microbiome‐Linked Mechanisms

Phytotherapy Research, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as a major global health burden, yet effective pharmacological options remain limited. Recent advances highlight the gut microbiome as a key modulator of liver metabolism, inflammation, and fibrosis, making it a promising therapeutic target.
Jeong In Seo, Su Min Kim, Hye Hyun Yoo
wiley   +1 more source

The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study

Diabetology & Metabolic Syndrome
Background and Aim The association between biliary disorders with weight reduction enhanced by GLP-1RAs was observed frequently, nevertheless, the relative risk of the clinically relevant cholelithiasis was not specified clearly among different GLP-1RAs.
Mohammed Ali Gameil, Elshahat Ali Ahmed Mohamed Yousef, Rehab Elsayed Marzouk, Mohamed H. Emara, Abeer H. Abdelkader, Rasha Ibrahim Salama   +5 more
doaj   +1 more source

Effectiveness of a Psychiatrist‐Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Psychotropic medications are associated with serious metabolic adverse effects, which contribute to an increased risk of cardiometabolic comorbidities in patients with severe mental illness (SMI). Several intervention strategies are available to mitigate these metabolic adverse effects; however, data on their utility in real‐world ...
Nicolette Stogios, Femin Prasad, Riddhita De, Kateryna Maksyutynska, Akash PrasannaKumar, Vittal Korann, Tariq Ahmed, Marcos Sanches, Leah Burton, Mohammed A. Alarabi, Tanner Isinger, Michelle Desanti, Rebecca Oliveira, Daphne J. Korczak, Ariel Graff‐Guerrero, Gary Remington, Margaret K. Hahn, Sri Mahavir Agarwal   +17 more
wiley   +1 more source

Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway

Journal of Cancer Research and Clinical Oncology
Aims Researches have shown that diabetes mellitus (DM) can promote the risk and progression of oral squamous cell carcinoma (OSCC). Semaglutide, a glucagon-like peptide-1 receptor agonist, is currently employed to treat type 2 diabetes mellitus (T2DM ...
Can Wang, Zhengzheng Wu, Jiaying Zhou, Bin Cheng, Yulei Huang   +4 more
doaj   +1 more source